IL-33 and IL-37: A Possible Axis in Skin and Allergic Diseases

Int J Mol Sci. 2022 Dec 26;24(1):372. doi: 10.3390/ijms24010372.

Abstract

Interleukin (IL)-37 and IL-33 are among the latest cytokines identified, playing a role in several inflammatory conditions, spanning from systemic conditions to tumors to localized diseases. As newly discovered interleukins, their role is still scarcely understood, but their potential role as therapeutic targets or disease activity markers suggests the need to reorganize the current data for a better interpretation. The aim of this review is to collect and organize data produced by several studies to create a complete picture. The research was conducted on the PubMed database, and the resulting articles were sorted by title, abstract, English language, and content. Several studies have been assessed, mostly related to atopic dermatitis and immunologic pathways. Collective data demonstrates a pro-inflammatory role of IL-33 and an anti-inflammatory one for IL-37, possibly related to each other in an IL-33/IL-37 axis. Although further studies are needed to assess the safety and plausibility of targeting these two interleukins for patients affected by skin conditions, the early results indicate that both IL-33 and IL-37 represent markers of disease activity.

Keywords: IL-33; IL-37; allergic diseases; asthma; atopic dermatitis; contact dermatitis; inflammation; interleukin; psoriasis; skin.

Publication types

  • Review

MeSH terms

  • Cytokines / metabolism
  • Dermatitis, Atopic* / drug therapy
  • Humans
  • Hypersensitivity* / metabolism
  • Interleukin-33 / metabolism
  • Interleukins / metabolism
  • Skin / metabolism

Substances

  • Interleukin-33
  • Interleukins
  • Cytokines

Grants and funding

This research received no external funding.